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Economic evaluation of screening
for open-angle glaucoma
Rodolfo A. Herna´ndez, Jennifer M. Burr, Luke D. Vale (for the OAG
Screening Project Group)
University of Aberdeen
Objectives: The aim of this study was to assess the cost-effectiveness of screening for
open-angle glaucoma (OAG) in the United Kingdom, given that OAG is an important
cause of blindness worldwide.
Methods: A Markov model was developed to estimate lifetime costs and benefits of a
cohort of patients facing, alternatively, screening or current opportunistic case finding
strategies. Strategies, varying in how screening would be organized (e.g., invitation for
assessment by a glaucoma-trained optometrist [GO] or for simple test assessment by a
technician) were developed, and allowed for the progression of OAG and treatment
effects. Data inputs were obtained from systematic reviews. Deterministic and
probabilistic sensitivity analyses were performed.
Results: Screening was more likely to be cost-effective as prevalence increased, for
40 year olds compared with 60 or 75 year olds, when the re-screening interval was greater
(10 years), and for the technician strategy compared with the GO strategy. For each age
cohort and at prevalence levels of ≤1 percent, the likelihood that either screening strategy
would be more cost-effective than current practice was small. For those 40 years of age,
“technician screening” compared with current practice has an incremental
cost-effectiveness ratio (ICER) that society might be willing to pay when prevalence is
6 percent to 10 percent and at over 10 percent for 60 year olds. In the United Kingdom,
the age specific prevalence of OAG is much lower. Screening by GO, at any age or
prevalence level, was not associated with an ICER < £30,000.
Conclusions: Population screening for OAG is unlikely to be cost-effective but could be
for specific subgroups at higher risk.
Keywords: Economic evaluation, Glaucoma, Screening, Cost-effectiveness analysis,
Cost-utility analysis
Glaucoma is a progressive optic neuropathy leading to blind-
ness if untreated. Worldwide, glaucoma is the leading cause
of irreversible blindness and open-angle glaucoma (OAG)
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accounts for approximately 50 percent of glaucoma blind-
ness (22). In a developed country setting, the majority of
OAG cases will remain undiagnosed by current case finding
strategies (11).
Risk factors for developing OAG are raised intraocu-
lar pressure (IOP), increasing age, black ethnicity, family
history of glaucoma, myopia, and diabetes (11). A key cri-
terion for a screening program is that early detection leads
to a better outcome than late detection. A systematic re-
view (two trials, 500 patients) of treatment effectiveness,
demonstrated that treatment reduces the risk of progression
in early disease (19). Population screening for OAG might
allow the early treatment and, hence, reduce the incidence of
visual impairment and blindness. However, it is important to
know if the screening for OAG is cost-effective, but existing
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economic evaluations are insufficient for evidence-based rec-
ommendations (15). The aim of this study was to model the
cost-effectiveness of screening for OAG compared with cur-
rent practice, in the United Kingdom, of opportunistic case
finding.
METHODS
The Model
We developed a Markov model (MM) (Figure 1) (8;24).
Health state definitions (see Supplementary Box 1, which
can be viewed online at http://www.journals.cambridge.org/
jid_thc) were based on the severity of binocular visual field
loss, adapted from a scoring system of the integrated visual
field, reported by Crabb and colleagues (12).
The model structure allows individuals to enter as
healthy (no OAG), and at varying degrees of OAG severity.
Over time, healthy individuals can develop OAG (i.e., new
incident cases), whereas those with OAG can develop more
severe disease and eventual visual impairment. The treatment
states refer to treated disease at each stage. The absorbing
state in the model is death and individuals can move into this
state from any other state within the model.
The model allows for a cohort of the population, some
with OAG, to pass through different strategies. The model
identifies that strategy that leads to the largest proportion of
individuals with OAG “crossing the bridge” into treatment
(Figure 1). A complete version of the model can be obtained
from the authors.
Model Strategies
We considered three strategies within the model: current
practice and two alternative screening strategies. Current UK
practice involves the opportunistic identification of cases by
community optometrists as part of a routine eye test. There
are many tests and configurations of testing arrangements
that are potentially suitable for an OAG screening program;
the modeled pathways were determined by consensus by an
expert panel. The two alternative screening strategies vary in
how screening would be organized. In one, individuals are
invited for a screening examination by a glaucoma trained
optometrist and undergo a complete glaucoma assessment in-
volving a measure of IOP, an assessment of the optic nerve,
and a visual field test. In the second strategy, individuals are
invited for an automated test quantifying functional visual
field loss or structural damage of the optic nerve, together
with a measurement of IOP, by a technician and individuals
identified as at risk are then referred for a full glaucoma as-
sessment by a glaucoma optometrist. In all three strategies,
any individual identified as positive at the end of screening
or case finding would be referred to an ophthalmologist for
definitive diagnosis and, if necessary, treatment.
Glaucoma Treatments
Once OAG is diagnosed, we have assumed that treatment
would be initiated. There is a cascade of eye drop treatment
options for each disease stage as well as their combination
with laser or surgical treatment. Evidence on their effective-
ness suggested that these could be approximated by a single
effect size, but treatment might vary by OAG severity and
progression rate (11). We assumed initial medical treatment
by a beta blocker or prostaglandin analogue, followed by
an additional drop of another class of medications if initial
treatment was ineffective. For those for whom this strategy
fails, argon trabeculoplasty or surgery (trabeculectomy) is
Figure 1. Markov model for open-angle glaucoma. Circles represent health states, and the arrows show the possible directions
in which individuals could move at the end of each cycle, depending on the transition probabilities. The states considered in the
model were those thought to reflect care pathways for people with and without glaucoma. The first line represents the pathway
for undiagnosed individuals, whereas the bottom section of the figure reflects glaucoma progression for treated patients. The
observation state includes individuals considered suspect but without a definite diagnosis.
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the next treatment step. In addition to medications, treatment
involves visits to the ophthalmologist every 6 weeks at the
beginning of treatment and a full assessment every 6 months.
After surgery, the patient would be seen at an ophthalmol-
ogy outpatient clinic at 1, 2, 4, 8, 12, and 26 weeks after
surgery.
Parameter Estimates Used in the Model
We obtained the model parameter estimates (Tables 1a, b)
from a series of systematic reviews of test accuracy, epi-
demiology, treatment effectiveness, and cost-effectiveness as
well as other systematic, focused searches. Detailed descrip-
tion of the parameters estimates can be found in Burr and
colleagues (11).
Probabilities
Table 1a reports the prevalence, incidence, and progression
of glaucoma parameters used. As there were many potential
target groups, each with different risk levels, we ran the
model for a range of prevalence values, aiming to identify a
prevalence where screening might be considered worthwhile,
and thus the population most likely to benefit from screening.
Data on the annual probabilities of having an eye test, by
sex and age, came from the British Household Panel Survey
(BHPS) (4). We obtained screening acceptance data from the
epidemiology review (11). We did not identify any studies
reporting the diagnostic accuracy of current practice, thus
we derived sensitivity and specificity estimates from Tuck
(27), the most appropriate, in terms of geographical cover-
age, number of patients seen, and number of participating
optometrists.
The accuracy of the glaucoma optometrist testing was
taken from a recent study by Azuara-Blanco and colleagues
(7), a Scottish comparative, masked, performance study. Data
from the Baltimore Eye Survey (23) were used for the esti-
mation of the proportion of normal or OAG patients with one
of the main risk factors for OAG, IOP≥ 26 mm Hg (23). Es-
timation of the proportion of people able to perform the test
(rate of indeterminacy) required for the “technician” screen-
ing strategy came from the systematic review of screening
tests (11). The model used sensitivity and specificity values
for the technician further test equal to or greater than 0.8. As
the systematic review showed that no one test or test combina-
tion was clearly more accurate and acceptable, we included a
range of sensitivity and specificity values in the model, rather
than modeling the performance of one test or combination
thereof. Finally, ophthalmologist assessment was assumed as
the reference standard. For probabilistic sensitivity analysis,
we assumed beta distributions for all parameters except for
technician further test indeterminacy, sensitivity, and speci-
ficity, and the proportion of people referred for observation
as glaucoma suspects by an ophthalmologist’s diagnostic as-
sessment (uniform distributions).
Costs
Table 1b shows the cost data used (2006 pounds sterling).
We used a 2 percent inflation rate for adjustments into a
common price year, where no inflation rate indices were
available. Where no information on ranges was obtainable,
we assumed a triangular distribution and rates of 0.5 and
1.5 times the likeliest value were used as lower and upper
limits. We obtained the cost for the optometrist test from the
National Health Service (NHS) “sight” test fees (3). For the
purposes of costing, we assumed that the IOP testing used
Goldmann applanation tonometry (GAT) with disposable tips
and that the glaucoma optometrist assessment used the same
test combination as ophthalmologist diagnosis (a combina-
tion of IOP measurement by GAT, slit lamp examination,
funduscopy, and a visual field test). The cost of ophthal-
mologist diagnosis was based on the cost of two standard
ophthalmology outpatient consultations (5) and for the ob-
servation state cost where patients judged at risk would be
seen yearly for up to 5 years or until OAG was diagnosed.
We estimated the treatment costs from a European study
including data from 194 patients, containing data for the
United Kingdom by severity of glaucoma (26). The likeli-
est value for the cost of visual impairment was taken to be
the mean value of the last two disease stages (26) as these
corresponded to the visual impairment category used in this
study. We assumed a triangular distribution for probabilistic
sensitivity analysis. We used the NHS fees for optometrists
in Scotland for the glaucoma optometrist assessment (2),
and costs for the “technician screening strategy” from the
Scottish Diabetic Retinopathy Screening study (1), and the
screening invitation costs (Table 1b) from the same study.
Quality of Life and Utilities
We used EQ-5D utility estimates from a recent UK study in-
volving almost 300 participants (10), including a subjective
and objective assessment of glaucoma severity. We used the
objective scores for each health state for the base-case and
subjective scores in the sensitivity analysis (Table 1b). We
developed the utility state for visual impairment using weight
data for the glaucoma severe state and the relative difference
from Gupta and colleagues (14). We attached beta distribu-
tions to these glaucoma utility weights parameters (9). We
assumed that there were no differences in the utility between
undiagnosed OAG and treated OAG at each level of severity.
Base-Case Analysis
We ran the base-case analysis for cohorts of 40-, 60-, and
75-year-old males, for a range of prevalence values, for a
lifetime horizon with screening occurring every 3 years, and
conducted from the UK NHS perspective. The cycle length
was set at 1 year, and a 3.5 percent discount rate was used (6).
The results are presented in incremental cost-effectiveness ra-
tios (ICERs). We undertook probabilistic analyses for ranges
of OAG prevalence from 0.1 percent to 10 percent.
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Table 1a. Model Parameter Inputs
Distribution and values used
Probability Value Source to define the distribution
Cohort start age 40 Base case assumption 60 and 75 years old
Prevalence of glaucoma 0 to 0.2 Lee 2003 (18) 0.475 and 0.45 for 60 and 75 years old,
Proportion of glaucoma mild 0.50 Tielsch 1991 (25) respectively
Proportion of glaucoma moderate 0.30 Tielsch 1991 (25)
Proportion of glaucoma severe 0.15 Tielsch 1991 (25)
Proportion of visual impaired 0.05 Burr 2007 (11) 0.075 and 0.10 for 60 and 75 years old,
respectively
Incidence of glaucoma: Burr 2007 (11)
40 years old 0.0003 Burr 2007 (11) Triangular: min = 0.0001; likeliest =
0.0003; max = 0.0008
50 years old 0.0003 Burr 2007 (11) Triangular: min = 0.0001; likeliest =
0.0003; max = 0.0008
60 years old 0.0008 Burr 2007 (11) Triangular: min = 0.0002; likeliest =
0.0008; max = 0.0022
70 years old 0.00181 Burr 2007 (11) Triangular: min = 0.00068; likeliest =
0.00181; max = 0.0044
80 years old 0.00141 Burr 2007 (11) Triangular: min = 0.00097; likeliest =
0.00141; max = 0.01
Progression of glaucoma to:
Glaucoma moderate 0.25 Burr 2007 (11) Triangular: min = 0.125; likeliest =
0.25; max = 0.75
Glaucoma severe 0.11 Burr 2007 (11) Triangular: min = 0.055; likeliest =
0.11; max = 0.33
Visual impaired 0.1 Burr 2007 (11) Triangular: min = 0.05; likeliest = 0.1;
max = 0.30
Risk ratio treated–nontreated 0.65 Burr 2007 (11) Lognormal (mean = −0.43; SD = 0.148)
Mortality Various Burr 2007 (11)
Probabilities of having an eye
test in current practice:
40 to 59 0.248 Regression analysis on BHPS data (11) Normal (mean = 0.248;
SE = 0.0019142)
60 to 75 0.3769 Regression analysis on BHPS data (11) Normal (mean = 0.3769;
SE = 0.0046524)
75 and over 0.42 Regression analysis on BHPS data (11) Normal (mean 0.42;
SE = 0.0051359)
Screening Acceptance. All groups 0.78 Range: min from Rotterdam study
(29); max from Rhondda Valley
study (16)
Triangular: min = 0.66; likeliest = 0.78;
max = 0.918
Optometrist test sensitivity 0.32 Tuck 1991 (27) Beta: n = 1378; r = 436
Optometrist test specificity 0.99 Tuck 1991 (27) Beta: n = 274,228; r = 273,614
Glaucoma optometrist test sensitivity 0.73 Azuara Blanco 2007 (7) Beta: n = 33, r = 24
Glaucoma optometrist test specificity 0.96 Azuara Blanco 2007 (7) Beta: n = 67, r = 64
Proportion of normal with IOP < 26 0.96 Burr 2007 (11) Beta: n = 5682, r = 5455
Proportion of glaucoma with IOP ≥ 26 0.35 Burr 2007 (11) Beta: n = 20, r = 7
Technician further test indeterminacy 0.1 Burr 2007 (11) Uniform: 0.06–0.20
Technician further test sensitivity 0.8 Assumption Uniform: 0.8–1
Technician further test specificity 0.8 Assumption Uniform: 0.8–1
Ophthalmologist test sensitivity 1 Assumption None defined
Ophthalmologist test specificity 1 Assumption None defined
Ophthalmologist observation proportion 0.43 Henson. Manchester Glaucoma
Optometry scheme 2005 data
(personal communication, D
Henson, 2006)
Uniform: 0.39–0.47
IOP, intraocular pressure; BHPS, British Household Panel Survey.
Sensitivity Analysis
One-way, two-way, and multiway sensitivity analyses for
the main parameters within the model were conducted, al-
most all of which were combined with probabilistic sensi-
tivity analysis. In these analyses, we explored the effects of
longer screening intervals (e.g., 5 and 10 years) and varying
the annual probability of a community optometrist eye test
(2 percent, 13 percent, 37 percent) uptake rates using one-way
206 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 24:2, 2008
Economic evaluation of screening for open-angle glaucoma
Table 1b. Model Parameter Inputs: Costs and Utilities
Value Distribution and values used
Costs (£) Source to define the distribution
Optometrist test 18.39 Department of Health (3) Triangular: min = 9.20; likeliest =
18.39; max = 27.59
Ophthalmologist diagnosis tests 133 Scotland National Statistics (5) Triangular: min = 77; likeliest = 133;
max = 397
Glaucoma mild treatment 420 Traverso 2005 (26) Triangular: min = 210; likeliest = 420;
max = 630
Glaucoma moderate treatment 473 Traverso 2005 (26) Triangular: min = 236.5; likeliest = 473;
max = 709.5
Glaucoma severe treatment 376 Traverso 2005 (26) Triangular: min = 188; likeliest = 376;
max = 564
Visual impairment annual cost 669 Traverso 2005 (26) Triangular: min = 585.41; likeliest =
669; max = 752.06
Screening invitation 10.45 NHS Quality Improvement Scotland (1)a Triangular: min = 5.23; likeliest =
10.45; max = 15.68
Glaucoma Optometrist test 46.5 Scottish Executive (3)b Triangular: min = 23.25; likeliest =
46.50; max = 69.75
Technician IOP tests 10.63 NHS Quality Improvement Scotland (1) Triangular: min = 5.32; likeliest =
10.63; max = 15.95
Technician 2nd test 10.63 NHS Quality Improvement Scotland (1) Triangular: min = 5.32; likeliest =
10.63; max = 15.95
Quality of Life Utility
weight
Source Distribution, and values used to define
the distribution
Normal 1 Assumption None
Glaucoma mild 0.8015 Burr 2007 (10) Beta (alpha = 8.2, beta = 2)
Glaucoma moderate 0.7471 Burr 2007 (10) Beta (alpha = 11.4, beta = 3.5)
Glaucoma severe 0.7133 Burr 2007 (10) Beta (alpha = 1.2, beta = 0.4)
Visual impaired 0.5350 Developed using data from Gupta 2005 (14) Lognormal, mu = −0.31029, sigma =
0.16631
a Take into account the cost for national coordination, local health board coordination, screening offices and call and recall, development and maintenance
of call and recall software, and development and maintenance of image capture software.
b The Scottish eye examination includes a full eye examination, visual field, and IOP (e.g., with non-contact tonometry), and supplementary exams if
clinically indicated (e.g., applanation pressures and threshold fields).
NHS, National Health Service; IOP, intraocular pressure.
sensitivity analysis. We varied the sensitivity and specificity
of the technician test within plausible ranges of 0.5 to 1.0 for
sensitivity and 0.8 to 1.0 for specificity.
Additionally, we performed several targeted sensitivity
analyses on a 40-year-old cohort, at a 5 percent (except where
otherwise stated) OAG prevalence rate and a 10-year screen-
ing interval (a combination that seemed most likely to be
cost-effective). As the group of individuals with higher OAG
prevalence rate would have a higher chance of visiting the
optometrist, we conducted an analysis assuming 1.5 times
and twice the probability of having an eye test for current
practice strategy. We used alternative triangular probabil-
ity distributions for progression and incidence using lower
and upper base-case limits as more likely values. We also
explored the impact of using subjective glaucoma severity-
based health state utilities (10). We also conducted high and
low cost scenario analyses.
Finally, we used one-way sensitivity analysis to identify
threshold values for the annual cost of visual impairment to
explore the effect of widening the perspective of the analysis.
This final analysis was conducted for 1 percent and 5 percent
prevalence rate of OAG.
RESULTS
Table 2 reports the estimated relative cost-effectiveness by
screening strategy at different levels of prevalence of OAG
for cohorts 40, 60, and 75 years of age, respectively. In each
analysis as prevalence increases, costs increase and quality-
adjusted life-years (QALYs) fall for all three strategies and
all age cohorts. In each analysis at each prevalence level and
age group considered, current practice is the least costly but
also the least effective of the three strategies. Adopting a
“technician” strategy is more effective but more costly than
current practice and screening by a glaucoma optometrist is
more effective but more costly than the “technician” screen-
ing strategy.
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Table 2. Base-Case Results: Incremental Cost-Effectiveness for the Selected Start Age Cohorts by Prevalence Rate
40-year-old cohort 60-year-old cohort 75-year-old cohort
Prevalence Strategy Cost (£) QALYs ICER Cost (£) QALYs ICER Cost (£) QALYs ICER
1.0% Current practice 257.40 19.231 187.10 12.477 103.47 6.905
Technician 520.36 19.233 107,938 364.37 12.479 134,060 210.76 6.905 200,028
GO 617.34 19.234 398,881 430.42 12.479 409,416 250.74 6.905 521,062
2.0% Current practice 333.89 19.166 232.42 12.438 125.01 6.884
Technician 608.76 19.170 65,924 418.47 12.440 88,094 238.87 6.885 137,032
GO 705.86 19.171 240,717 484.79 12.440 264,869 279.22 6.885 350,449
4.0% Current practice 486.85 19.036 323.06 12.360 168.11 6.843
Technician 785.57 19.044 39,118 526.67 12.363 55,160 295.11 6.845 89,440
GO 882.89 19.045 134,460 593.52 12.364 156,016 336.17 6.845 213,985
6.0% Current practice 639.82 18.906 413.71 12.281 211.20 6.802
Technician 962.38 18.918 29,051 634.87 12.286 41,963 351.35 6.804 69,757
GO 1,059.93 18.919 93,416 702.25 12.287 111,083 393.12 6.804 155,507
8.0% Current practice 792.79 18.777 504.35 12.203 254.30 6.761
Technician 1,139.19 18.791 23,775 743.07 12.209 34,851 407.58 6.764 58,999
GO 1,236.97 18.793 71,648 810.98 12.210 86,547 450.08 6.764 123,022
10.0% Current practice 945.76 18.647 594.99 12.124 297.39 6.720
Technician 1,316.00 18.665 20,527 851.27 12.132 30,405 463.82 6.723 52,218
GO 1,414.00 18.667 58,158 919.71 12.133 71,088 507.03 6.723 102,350
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years; GO, “glaucoma optometrist” strategy.
For each age group considered, the ICER from adopt-
ing “technician” screening compared with current practice
falls as prevalence increases. Similarly, for each age group
considered, the ICER gained from adopting “glaucoma op-
tometrist” screening compared with “technician” screening
also falls as prevalence increases.
In the base-case analysis for a 40-year-old cohort, a
“technician” screening strategy compared with current prac-
tice has an ICER that society might be willing to pay when
prevalence is approximately 6 percent to 10 percent (Table 2)
and over 10 percent for a 60-year-old. For a 75-year-old co-
hort, current practice strategy might be considered worth-
while (Table 2), even when prevalence level is 20 percent
(not shown). Furthermore, for no age cohort and no preva-
lence level is screening by the glaucoma optometrist instead
of screening by the technician associated with an ICER <
£30,000.
Sensitivity Analysis Performed around the
Base Case
The probabilistic sensitivity analysis (Table 3) indicates that,
for every cohort group and at prevalence levels of 1 percent or
less, the likelihood that any screening strategy would be more
cost-effective than current practice is small. At 5 percent
prevalence for the 40-year-old cohort level, there is less than
50 percent likelihood that “technician” screening might be
considered cost-effective at a willingness to pay for a QALY
of £30,000. Glaucoma optometrist screening is unlikely to
be considered cost-effective.
Increasing the screening interval reduces the ICER for
each age group and each prevalence level, as OAG on av-
erage, progresses relatively slowly and QALY reduction
is more than compensated for by costs reduction. Vary-
ing the annual uptake rates for community optometrist
testing led to both cost and QALYs rising as uptake in-
creased. The higher the uptake, the better the current prac-
tice strategy performs. The results of the sensitivity anal-
ysis on sensitivity and specificity of the test following the
measurement of IOP in the “technician” strategy indicate
that the ICER is relatively insensitive to changes in these
variables.
Targeted Sensitivity Analyses
Further sensitivity analysis for a 40-year-old cohort, 10-
year screening interval and a 5 percent OAG prevalence
indicated that screening with the “technician” strategy
might be considered worthwhile (see Supplementary Ta-
ble 1a, which can be viewed online at http://www.journals.
cambridge.org/jid_thc). Probabilistic sensitivity analysis
demonstrates that the uncertainty around model parameter
estimates was important, for example, even though the ICER
for the comparison of the “technician” with the current prac-
tice strategy is £20,571, there is only 42 percent likelihood
that the cost per QALY would be less than £20,000.
Furthermore, sensitivity analyses on uptake of commu-
nity optometrist testing demonstrated that the QALY gain for
the current practice strategy more than compensates for its
higher cost. The ICER of the “technician” strategy compared
with current practice increased, as did the ICER for the com-
parison of the “glaucoma optometrist” strategy compared
with the “technician” strategy. Changes to the rate of OAG
incidence did not greatly alter cost-effectiveness, however; as
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Table 3. Likelihood of a Strategy Being Cost-Effective for Selected Age Cohorts Start Age and Screening Intervals
Probability of being cost-effective for different threshold values
for society’s willingness to pay for a QALY (%)
1% prevalence of OAG 5% prevalence of OAG
Cohort start Screening
age (years) interval Strategy 10,000 20,000 30,000 50,000 10,000 20,000 30,000 50,000
40 3 years Current practice 100.0% 98.8% 93.9% 78.5% 94.4% 71.5% 50.8% 34.9%
(base case) Technician 0.0% 1.2% 5.9% 21.0% 5.4% 27.9% 48.0% 61.3%
GO 0.0% 0.0% 0.2% 0.5% 0.2% 0.6% 1.2% 3.8%
5 years Current practice 100.0% 97.1% 88.2% 69.2% 87.6% 58.6% 43.2% 29.2%
Technician 0.0% 2.7% 11.5% 30.1% 12.2% 40.2% 53.3% 60.4%
GO 0.0% 0.2% 0.3% 0.7% 0.2% 1.2% 3.5% 10.4%
10 years Current practice 99.8% 92.1% 79.1% 56.2% 82.5% 54.3% 40.2% 29.6%
Technician 0.2% 7.7% 20.3% 42.5% 16.7% 42.3% 51.4% 51.1%
GO 0.0% 0.2% 0.6% 1.3% 0.8% 3.4% 8.4% 19.3%
60 3 years Current practice 100.0% 98.4% 92.9% 79.2% 96.4% 79.3% 64.0% 46.1%
(base case) Technician 0.0% 1.5% 6.9% 20.2% 3.5% 20.1% 34.7% 50.5%
GO 0.0% 0.1% 0.2% 0.6% 0.1% 0.6% 1.3% 3.4%
5 years Current practice 100.0% 97.2% 90.0% 74.4% 93.1% 73.3% 56.7% 40.3%
Technician 0.0% 2.7% 9.6% 24.7% 6.7% 25.7% 40.5% 50.8%
GO 0.0% 0.1% 0.4% 0.9% 0.2% 1.0% 2.8% 8.9%
10 years Current practice 100.0% 95.1% 86.9% 69.3% 88.1% 63.9% 49.3% 34.9%
Technician 0.0% 4.8% 12.7% 29.5% 11.5% 33.6% 44.0% 48.4%
GO 0.0% 0.1% 0.4% 1.2% 0.4% 2.5% 6.7% 16.7%
75 3 years Current practice 100.0% 99.6% 96.1% 88.1% 99.1% 89.8% 78.7% 64.0%
(base case) Technician 0.0% 0.4% 3.7% 11.5% 0.9% 9.9% 20.4% 33.8%
GO 0.0% 0.0% 0.2% 0.4% 0.0% 0.3% 0.9% 2.2%
5 years Current practice 100.0% 99.6% 96.5% 88.1% 98.2% 86.9% 74.5% 59.9%
Technician 0.0% 0.4% 3.5% 11.9% 1.7% 12.4% 24.2% 34.9%
GO 0.0% 0.0% 0.0% 0.0% 0.1% 0.7% 1.3% 5.2%
10 years Current practice 100.0% 99.1% 94.6% 84.3% 96.1% 82.2% 69.7% 53.8%
Technician 0.0% 0.9% 5.2% 15.1% 3.8% 16.9% 27.9% 37.5%
GO 0.0% 0.0% 0.2% 0.6% 0.1% 0.9% 2.4% 8.7%
QALYs, quality-adjusted life-years; OAG, open-angle glaucoma; GO, “glaucoma optometrist” strategy.
the rate of progression increased (see Supplementary
Table 1b “high,” which can be viewed online at http://
www.journals.cambridge.org/jid_thc), then the likelihood
that either screening strategies could be considered cost-
effective increased, as screening is likely to detect more cases
and, hence, delay progression. Using alternative valuations
for health utilities, varying the cost of diagnosis by the oph-
thalmologist, the costs of treatment, inviting people to be
screened, or their subsequent tests had little effect on cost-
effectiveness.
The threshold analysis for the cost of visual impair-
ment and 1 percent OAG prevalence shows the “technician”
strategy dominates the current practice strategy when the
annual cost for visual impairment is around £16,000; more-
over, the ICER is less than £30,000 if the cost of visual
impairment is greater than £8,800. For the “glaucoma op-
tometrist” strategy to be considered cost-effective compared
with the “technician” strategy would require the annual cost
of visual impairment to be greater than £40,000 (see Supple-
mentary Figure 1, which can be viewed online at http://www.
journals.cambridge.org/jid_thc).
DISCUSSION
We conducted a model based cost-utility analysis of the
screening for OAG that compared technician- or glaucoma
optometrist-based screening with current practice (e.g., op-
portunistic case finding). Data to populate this model came
from a series of systematic reviews of the literature and incor-
porated extensive sensitivity analyses to the imprecision sur-
rounding parameter estimates and other forms of uncertainty.
The distributions used to characterize the statistical impre-
cision varied by parameter but were consistent with prior
experience about which type of distribution would be appro-
priate for the type and nature of the data available (17;21).
Although, the best use was made of, in some cases, limited
data, further information on the value of almost all parameter
estimates would be useful.
Our study suggests that general population screening is
unlikely to be cost-effective as the prevalence of OAG in
the younger cohorts (estimated 0.9 percent at age 50), most
likely to enjoy the benefits of screening for longer, is too
low. However, screening might be cost-effective for selected
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“at risk” subgroups. Targeted screening of 40 to 50 year
olds with a risk factor (e.g., black ethnicity or those with a
family history of glaucoma) is more likely to be cost-effective
assuming a prevalence of OAG between 3 and 4 percent and
a screening interval of 10 years. These groups account for
approximately 6 percent of the UK population.
In our model, costs increase as prevalence increases be-
cause a larger proportion of individuals in the cohort incur
the costs of diagnosis and the continuing costs of treating the
OAG. The mean cost per person and estimated QALYs are
higher for the 40-year-old cohort than the older cohorts be-
cause they are less likely to die during the time horizon of the
model. Estimated mean QALYs fall as prevalence increases
because a greater proportion of the cohort experiences the
adverse health effects of OAG.
The model was sensitive to the annual costs for visual
impairment (VI). The higher the annual cost of VI, the more
likely screening is to become cost-effective. The thresholds
for this to happen are not dissimilar to the costs estimated
by Meads and Hyde (20) (e.g., annual cost of VI of approx-
imately £7900 for the first year and £7700 for subsequent
years).
The more likely people are to have an eye test in the
current practice strategy (i.e. the comparator), the less likely
screening is cost-effective. A relative high attendance for
eye tests in the current practice setting might explain the
somewhat counterintuitive results.
A review of other cost-effectiveness evaluations of
screening for OAG (15) identified only one previous study
that attempted to compare an active screening strategy with
current practice (13). This study also concluded that screen-
ing for OAG was not cost-effective. However, a recently pub-
lished cost-utility analysis of OAG screening in Finland (28)
concluded that a screening program could be cost-effective,
especially in older groups for whom prevalence rates are
higher. In contrast to the Finnish analysis, our model as-
sumes that no one in the cohorts was receiving treatment
before screening or opportunistic case detection. The net
effect of relaxing this assumption is unclear. Stopping in-
appropriate glaucoma treatment could make screening more
cost-effective. However, care should be taken to consider cost
and consequences of those individuals identified as inappro-
priately treated (e.g., raised IOP but no glaucomatous visual
field loss). Furthermore, if individuals were treated appro-
priately, there would be no benefit from screening and its
cost-effectiveness would be lower. A further factor driving
the difference between the conclusions of the Finnish study
and our work was the inclusion by the Finnish study of the
costs of visual impairment. Our results were also sensitive to
the inclusion of these higher costs.
One limitation of our study was that the utility associated
with treated and untreated glaucoma was assumed to be the
same. This strategy ignores any utility loss associated with
adverse effects of treatment. Adverse treatment effects are
estimated to reduce quality of life by between 7 and 11 per-
cent, depending upon severity of these effects, as estimated
by Burr and colleagues (10). Future studies should consider
using a measure appropriate for use within an economic eval-
uation in people whose glaucoma has not progressed, both
before and after treatment has started.
The systematic review identified insufficient evidence
to meaningfully distinguish between the variety of tests that
might be used in practice. This finding led to the simplifi-
cation of the care pathways where the battery of tests used
by a glaucoma optometrist was represented by a single value
for sensitivity and specificity of a test. This and other sim-
plifications (such as the small number of stages to represent
disease progression) were made after consultation with ex-
perts. Further research to develop the model structure and the
associated parameter values is required.
Overall, although the evidence on cost-effectiveness
should be treated cautiously, the results indicate some pa-
tient groups for which the organization of targeted screen-
ing, that is, a surveillance program, might be given further
consideration. However, care pathways would need to be
in place for those not eligible for screening. In situations
where it might be feasible to organize a service for the target
population further primary research on the effectiveness and
cost-effectiveness of such a program is required. A random-
ized controlled trial is the optimal study design, but before
such a study being undertaken, further research is needed to
develop feasible strategies to identify individuals in “at risk”
groups and the optimal configuration of screening strategies
to maximize screening attendance.
CONCLUSION
General population screening is unlikely to be considered
cost-effective. However, screening for OAG is associated
with an ICER that society might be willing to pay for par-
ticular cohorts of patients, namely, targeted screening for
50 year olds at high risk (e.g., family history and/or black
ethnicity) may be worthwhile. Results are sensitive to the
assumed annual cost of VI. Further data related to both im-
proving the estimates available for some of the parameters
in the model and also from a well-designed controlled study
comparing viable screening strategies in the cohorts of pa-
tients for whom this research has indicated that screening
might be potentially cost-effective are required to confirm
the findings.
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